Plasmapp (CEO: Youbong Lim) successfully entered the KOSDAQ market after completing the listing ceremony held at the Korea Exchange (located in Yeouido, Seoul) on the 21st.

Attending the listing ceremony were Plasmapp CEO Youbong Lim, along with employees and officials from Mirae Asset Securities, who served as the lead underwriter.

Founded in 2015 in the plasma physics laboratory of the Korea Advanced Institute of Science and Technology (KAIST), Plasmapp is a bio-plasma deep tech company. The company develops medical device care solutions utilizing innovative bio-plasma technology, including surgical device low-temperature sterilization (biological inactivation) solutions and implant regenerative activation solutions. Plasmapp has acquired 174 patents and certifications from 45 countries, including the U.S. FDA, and generates revenue in over 55 countries, continuing its rapid growth year after year.

Plasmapp plans to utilize the proceeds from the IPO as capital expenditure (CAPEX) for expansion and research and development funds to establish a foundation for sustainable growth. Furthermore, the company aims to expand and commercialize its application scope into various industries based on plasma solutions, driving medium to long-term growth.

Plasmapp CEO Youbong Lim expressed gratitude to all those who contributed to the successful entry into the KOSDAQ market, stating, "I thank everyone who helped us successfully enter the KOSDAQ market," and expressed determination to grow into a global company by creating various solutions in the healthcare industry following the listing.

▲ The listing ceremony for Plasmapp on the KOSDAQ market took place at the Korea Exchange in Yeouido, Seoul, on the 21st.

CEO Youbong Lim of Plasmapp is seen celebrating the listing and signing the guestbook. (Photo by Plasmapp)